Abbott Expects RA Agent D2E7 To Capture 25% Of Market, Touts Production
Executive Summary
Abbott predicts it has existing production capacity for its rheumatoid arthritis treatment D2E7 (adalimumab) to serve the market up to five years, even at ambitious growth projections.
You may also be interested in...
Abbott Humira Marketing Will Challenge RA Competitors On Dosing, Efficacy
Abbott will highlight Humira dosing convenience, efficacy and price to encourage switching of rheumatoid arthritis patients from Amgen/Wyeth's Enbrel or Johnson & Johnson's Remicade
Abbott Humira Marketing Will Challenge RA Competitors On Dosing, Efficacy
Abbott will highlight Humira dosing convenience, efficacy and price to encourage switching of rheumatoid arthritis patients from Amgen/Wyeth's Enbrel or Johnson & Johnson's Remicade
Abbott D2E7 Monotherapy Use Should Afford Faster FDA Review, Abbott Says
Abbott is focusing on the need for a regular supply of an anti-TNF agent that can be dosed without methotrexate as a justification for requiring a faster review of D2E7 at FDA